Form 4: Director Carl Dambkowski Sells Oruka Therapeutics Shares
Statement of Changes in Beneficial Ownership
Director Carl Dambkowski sold 35,000 shares of Oruka Therapeutics, Inc. common stock via a pre-arranged 10b5-1 trading plan.
Summary
- Director Carl Dambkowski sold a total of 35,000 shares of Oruka Therapeutics (ORKA) common stock.
- The sales occurred on June 11, 2026 (22,417 shares) and June 12, 2026 (12,583 shares).
- The transactions were executed at weighted average prices of $70.1343 and $70.109 per share, respectively.
- Following these transactions, the director retains beneficial ownership of 38,743 shares.
- The sales were conducted under a Rule 10b5-1 trading plan established on February 19, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sales were conducted through a pre-planned, automated trading program.
Positives
- The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.
Negatives
- The transaction represents a reduction in the director's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.
Future Outlook
No forward-looking guidance or operational outlook was provided in this filing.
Industry Context
StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance activity and typically does not reflect a change in company strategy or fundamental health.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Shareholders should note the reduction in insider ownership, though the systematic nature of the sale suggests it is for personal financial planning rather than a reaction to company performance.
Key Dates
| Date | Description |
|---|---|
| 2026-02-19 | Date the Rule 10b5-1 trading plan was established. |
| 2026-06-11 | First date of share sales. |
| 2026-06-12 | Second date of share sales and filing date. |
Keywords
Oruka Therapeutics, ORKA, Insider Trading, Form 4, SEC Filing, Director Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.